List of works - Maria Di Bartolomeo

A double-blind, randomized, placebo-controlled, phase 2 study of maintenance enzastaurin with 5-fluorouracil/leucovorin plus bevacizumab after first-line therapy for metastatic colorectal cancer

scientific article published on 27 December 2011

A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer

scientific article published on 4 September 2015

Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation.

scientific article

Adjuvant chemotherapy for gastric cancer: current evidence and future challenges.

scientific article published on April 2014

Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial

scientific article published on 29 March 2019

BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis

scientific article published on 7 July 2015

BRAF in metastatic colorectal cancer: the future starts now.

scientific article

Bax expression is predictive of favorable clinical outcome in chemonaive advanced gastric cancer patients treated with capecitabine, oxaliplatin, and irinotecan regimen

scientific article

Bevacizumab treatment in the elderly patient with metastatic colorectal cancer

scientific article

Bevacizumab-based neoadjuvant chemotherapy for colorectal cancer liver metastases: Pitfalls and helpful tricks in a review for clinicians.

scientific article published on 25 April 2015

Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer

scientific article published on 06 September 2007

Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II study

article

Chemoradiotherapy as preoperative treatment in locally advanced unresectable pancreatic cancer patients: results of a feasibility study11Data management by Italian Trials in Medical Oncology (I.T.M.O.) Scientific Service

article

Chemotherapy or targeted therapy as second-line treatment of advanced gastric cancer. A systematic review and meta-analysis of published studies

scientific article

Chronomodulated Capecitabine and Adjuvant Radiation in Intermediate-risk to High-risk Rectal Cancer

scientific article published on 01 December 2014

Circulating biomarkers in advanced colorectal cancer patients randomly assigned to three bevacizumab-based regimens

scientific article

Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS-BRAF wild-type colorectal cancer receiving cetuximab or panitumumab.

scientific article

Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group

scientific article published on 01 January 1996

Combination goserelin and tamoxifen therapy in premenopausal advanced breast cancer: a multicentre study by the ITMO group. Italian Trials in Medical Oncology

scientific article

Combination or single-agent chemotherapy as adjuvant treatment of gastric cancer: A systematic review and meta-analysis of published trials

scientific article published on 9 October 2015

Combined liver and pancreatic islets transplantation in man using cyclosporin immunosuppression

scientific article published on 01 January 1994

DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan

scientific article

Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients

scientific article published on 21 October 2008

Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer

scientific article published on 4 November 2015

Doxifluridine in colorectal cancer patients resistant to 5-fluorouracil (5-FU) containing regimens

scientific article published on 01 April 1997

Early tumour shrinkage as a prognostic factor and surrogate end-point in colorectal cancer: a systematic review and pooled-analysis

scientific article published on 17 March 2015

Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours

scientific article

Efficacy of treatment with irinotecan and oxaliplatin combination in FU-resistant metastatic colorectal cancer patients

scientific article

Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor.

scientific article

Epirubicin, etoposide and cisplatin in advanced pancreatic carcinoma

scientific article published on 01 January 1993

Etoposide, doxorubicin and cisplatin (EAP) treatment in advanced gastric carcinoma: a multicentre study of the Italian Trials in Medical Oncology (I.T.M.O.) Group

scientific article

FOLFIRI with cetuximab or bevacizumab: FIRE-3

scientific article published on 24 November 2014

FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxoma

scientific article

Feasibility of sequential therapy with FOLFIRI followed by docetaxel/cisplatin in patients with radically resected gastric adenocarcinoma. A randomized phase III trial

scientific article

First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis

scientific article published on 5 June 2015

GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study

scientific article published on 6 May 2016

Gain of ALK gene copy number may predict lack of benefit from anti-EGFR treatment in patients with advanced colorectal cancer and RAS-RAF-PI3KCA wild-type status

scientific article

HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research.

scientific article published on 31 August 2016

Hepatic colorectal cancer metastases showing a distinctive pattern of pathological response after metronomic capecitabine and bevacizumab.

scientific article published on 21 January 2012

Impact on survival of timing and duration of adjuvant chemotherapy in radically resected gastric cancer

scientific article published on 30 March 2016

Incidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5-fluorouracil: a meta-analysis of published trials

scientific article

Is the standardized uptake value of FDG-PET/CT predictive of pathological complete response in locally advanced rectal cancer treated with capecitabine-based neoadjuvant chemoradiation?

scientific article published on 15 January 2013

Lack of Bax expression is associated with irinotecan-based treatment activity in advanced colorectal cancer patients.

scientific article published on 21 November 2012

Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT.

scientific article published on 3 July 2013

MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.

scientific article

Oral chemotherapy with doxifluridine and folinic acid in biliary tract cancer

scientific article published on 01 December 1995

Osteopontin, E-cadherin, and β-catenin expression as prognostic biomarkers in patients with radically resected gastric cancer.

scientific article published on 11 April 2015

PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients

article

Pathological features as predictors of recurrence after radical resection of gastric cancer

scientific article published on 01 February 2006

Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases

article

Perioperative Triplet Chemotherapy and Cetuximab in Patients With RAS Wild Type High Recurrence Risk or Borderline Resectable Colorectal Cancer Liver Metastases

scientific article published on 06 October 2016

Phase II Study of the Etoposide, Leucovorin and Fluorouracil Combination for Patients with Advanced Gastric Cancer Unsuitable for Aggressive Chemotherapy

scientific article published on 01 January 1995

Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis

scientific article

Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study

scientific article published on 27 March 2018

Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma

scientific article

Resection versus transplantation for liver metastases from neuroendocrine tumors

scientific article published on 01 February 2001

Role of BAX for outcome prediction in gastrointestinal malignancies.

scientific article published on 23 May 2013

Role of cMET in the development and progression of colorectal cancer

scientific article published on 03 September 2013

Role of the antiangiogenic agent bevacizumab in the treatment of elderly patients with metastatic colorectal cancer

scientific article published on February 2011

Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study.

scientific article published on 30 April 2009

Salvage treatment after r-interferon alpha-2a in advanced neuroendocrine tumors.

scientific article

Single agent panitumumab in KRAS wild-type metastatic colorectal cancer patients following cetuximab-based regimens: Clinical outcome and biomarkers of efficacy

scientific article published on 04 September 2013

Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope

scientific article

TP53 mutations in advanced colorectal cancer: the dark side of the moon.

scientific article published on 07 June 2014

The luteinising hormone–releasing hormone analogue triptorelin with or without the aromatase inhibitor formestane in premenopausal breast cancer: effects on bone metabolism markers

scientific article published on 01 December 2000

Treatment of carcinoid syndrome with recombinant interferon alpha-2a.

scientific article

Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenase

scientific article published on 21 April 2015

Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study

scientific article published on 23 January 2007

Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab.

scientific article published on 22 March 2016

List of works by Maria Di Bartolomeo

A double-blind, randomized, placebo-controlled, phase 2 study of maintenance enzastaurin with 5-fluorouracil/leucovorin plus bevacizumab after first-line therapy for metastatic colorectal cancer

A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer

Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation.

Adjuvant chemotherapy for gastric cancer: current evidence and future challenges.

Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial

BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis

BRAF in metastatic colorectal cancer: the future starts now.

Bax expression is predictive of favorable clinical outcome in chemonaive advanced gastric cancer patients treated with capecitabine, oxaliplatin, and irinotecan regimen

Bevacizumab treatment in the elderly patient with metastatic colorectal cancer

Bevacizumab-based neoadjuvant chemotherapy for colorectal cancer liver metastases: Pitfalls and helpful tricks in a review for clinicians.

Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer

Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II study

Chemoradiotherapy as preoperative treatment in locally advanced unresectable pancreatic cancer patients: results of a feasibility study11Data management by Italian Trials in Medical Oncology (I.T.M.O.) Scientific Service

Chemotherapy or targeted therapy as second-line treatment of advanced gastric cancer. A systematic review and meta-analysis of published studies

Chronomodulated Capecitabine and Adjuvant Radiation in Intermediate-risk to High-risk Rectal Cancer

Circulating biomarkers in advanced colorectal cancer patients randomly assigned to three bevacizumab-based regimens

Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS-BRAF wild-type colorectal cancer receiving cetuximab or panitumumab.

Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group

Combination goserelin and tamoxifen therapy in premenopausal advanced breast cancer: a multicentre study by the ITMO group. Italian Trials in Medical Oncology

Combination or single-agent chemotherapy as adjuvant treatment of gastric cancer: A systematic review and meta-analysis of published trials

Combined liver and pancreatic islets transplantation in man using cyclosporin immunosuppression

DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan

Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients

Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer

Doxifluridine in colorectal cancer patients resistant to 5-fluorouracil (5-FU) containing regimens

Early tumour shrinkage as a prognostic factor and surrogate end-point in colorectal cancer: a systematic review and pooled-analysis

Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours

Efficacy of treatment with irinotecan and oxaliplatin combination in FU-resistant metastatic colorectal cancer patients

Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor.

Epirubicin, etoposide and cisplatin in advanced pancreatic carcinoma

Etoposide, doxorubicin and cisplatin (EAP) treatment in advanced gastric carcinoma: a multicentre study of the Italian Trials in Medical Oncology (I.T.M.O.) Group

FOLFIRI with cetuximab or bevacizumab: FIRE-3

FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxoma

Feasibility of sequential therapy with FOLFIRI followed by docetaxel/cisplatin in patients with radically resected gastric adenocarcinoma. A randomized phase III trial

First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis

GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study

Gain of ALK gene copy number may predict lack of benefit from anti-EGFR treatment in patients with advanced colorectal cancer and RAS-RAF-PI3KCA wild-type status

HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research.

Hepatic colorectal cancer metastases showing a distinctive pattern of pathological response after metronomic capecitabine and bevacizumab.

Impact on survival of timing and duration of adjuvant chemotherapy in radically resected gastric cancer

Incidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5-fluorouracil: a meta-analysis of published trials

Is the standardized uptake value of FDG-PET/CT predictive of pathological complete response in locally advanced rectal cancer treated with capecitabine-based neoadjuvant chemoradiation?

Lack of Bax expression is associated with irinotecan-based treatment activity in advanced colorectal cancer patients.

Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT.

MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.

Oral chemotherapy with doxifluridine and folinic acid in biliary tract cancer

Osteopontin, E-cadherin, and β-catenin expression as prognostic biomarkers in patients with radically resected gastric cancer.

PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients

Pathological features as predictors of recurrence after radical resection of gastric cancer

Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases

Perioperative Triplet Chemotherapy and Cetuximab in Patients With RAS Wild Type High Recurrence Risk or Borderline Resectable Colorectal Cancer Liver Metastases

Phase II Study of the Etoposide, Leucovorin and Fluorouracil Combination for Patients with Advanced Gastric Cancer Unsuitable for Aggressive Chemotherapy

Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis

Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study

Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma

Resection versus transplantation for liver metastases from neuroendocrine tumors

Role of BAX for outcome prediction in gastrointestinal malignancies.

Role of cMET in the development and progression of colorectal cancer

Role of the antiangiogenic agent bevacizumab in the treatment of elderly patients with metastatic colorectal cancer

Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study.

Salvage treatment after r-interferon alpha-2a in advanced neuroendocrine tumors.

Single agent panitumumab in KRAS wild-type metastatic colorectal cancer patients following cetuximab-based regimens: Clinical outcome and biomarkers of efficacy

Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope

TP53 mutations in advanced colorectal cancer: the dark side of the moon.

The luteinising hormone–releasing hormone analogue triptorelin with or without the aromatase inhibitor formestane in premenopausal breast cancer: effects on bone metabolism markers

Treatment of carcinoid syndrome with recombinant interferon alpha-2a.

Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenase

Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study

Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab.